证券代码：300759 证券简称：康龙化成 康龙化成（北京）新药技术股份有限公司投资者关系活动记录表 编号：2023-02 | □特定对象调研 | □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 活动类别 | | | | □现场参观 | | | √其他 （电话会议） | | 参与单位名称及 | International, Inc.中国人保、华夏基金、银华基金、嘉实资产、广发基金、 | | | 华夏基金、建信养老、国寿养老、太平养老、平安养老、新华养老、中 | | | 国人寿、阳光资产、平安资产、富国基金、博时基金、鹏华基金、汇添 | | | 富基金、泰达宏利基金、天弘基金、海富通基金、中银基金、太平基金、 | | | 上投摩根基金、英大国际信托等 余家机构 余名参与人员 400 410 | | | 日 31 09:00-11:30 | | 地 点 | 公司会议室 | | 上市公司接待人 | | | 员姓名 | | | | 首席财务官、董事会秘书：李承宗先生 | | 投资者关系活动 | 年度报告 2022 进行分析解读。 2022 年度，公司实现营业收入超过 100 亿 ...

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the year 2022, representing a year-over-year increase of 25%[142]. - The company achieved a revenue of 1,026,628.82 million yuan in 2022, representing a year-on-year growth of 37.92%[30]. - The company reported a significant increase in revenue, reaching approximately 1.5 billion RMB, representing a year-over-year growth of 25%[10]. - The company provided a revenue guidance for 2023, expecting a growth rate of 20% to 25%[143]. - The company provided a positive outlook for 2023, projecting a revenue growth of 20% to 25% based on new product launches and market expansion strategies[10]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a growth of 25% year-over-year[132]. - The company reported a revenue increase of 25% year-over-year, reaching CNY 1.5 billion in 2022[135]. - The company achieved a total operating revenue for 2022 of ¥10,266,288,179.53, representing a 37.92% increase from ¥7,443,769,724.38 in 2021[58]. Profitability - The net profit attributable to shareholders for 2022 was ¥1,374,604,224.18, a decrease of 17.24% from ¥1,661,028,567.53 in 2021[14]. - The adjusted net profit attributable to shareholders was 183,427.10 million yuan, an increase of 25.46% compared to the previous year[30]. - The overall gross margin improved to 45%, up from 40% in the previous year, reflecting better operational efficiency and cost management[10]. - The gross margin for the main business reached 36.73%, up by 0.71 percentage points from the previous year[30]. - The gross profit margin for the scientific research and technology services sector improved slightly to 36.73%, up from 36.48% in the previous year[60]. Investment and R&D - Investment in R&D increased by 15%, totaling 300 million RMB, focusing on innovative drug development and advanced technologies[10]. - The R&D budget for 2023 is set at RMB 300 million, a 20% increase from the previous year[143]. - The company invested CNY 200 million in R&D for new technologies, focusing on advanced drug delivery systems[135]. - The company has established a comprehensive drug development service platform, focusing on small molecule research and development, and is expanding capabilities in large molecule and gene therapy services[91]. - The company is investing 150 million RMB in new technology for drug discovery to improve efficiency[132]. Market Expansion - The company plans to expand its market presence in Europe and North America, targeting a 10% market share in these regions by 2025[10]. - The company aims to strengthen its international service platform to provide cross-disciplinary and cross-regional solutions for clients[23]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[143]. - The company is actively pursuing mergers and acquisitions to strengthen its portfolio, with a budget of 500 million RMB allocated for potential acquisitions in 2023[10]. - The company is planning to expand its market presence in Asia, targeting a 20% increase in market share by 2025[122]. Client and Customer Engagement - User data showed that the number of active clients increased by 30%, reaching a total of 1,200 clients in 2022[10]. - User data showed an increase in active users by 30% year-over-year, reaching 2 million active users by the end of 2022[143]. - The company introduced approximately 800 new clients in 2022, diversifying its customer base[30]. - Customer satisfaction ratings improved to 85%, reflecting a 5% increase from the previous year[143]. Strategic Partnerships and Acquisitions - A new strategic partnership was announced with a leading pharmaceutical company to enhance drug development capabilities and accelerate commercialization efforts[10]. - The company completed a strategic acquisition to enhance its research capabilities, which is expected to contribute an additional 4,920,000 in revenue[119]. - The company completed an acquisition of a biotech firm for CNY 500 million, enhancing its product pipeline[135]. - The company is exploring partnerships with international firms to enhance its global reach and innovation[142]. Risk Management - The company emphasizes the importance of risk management and outlines potential risks and countermeasures in its future development outlook[3]. - The company has implemented measures to control market, liquidity, credit, operational, and legal risks associated with its hedging activities[83]. - The company has established a management system for futures and derivatives trading, ensuring compliance with operational norms and risk control measures[83]. Governance and Compliance - The company emphasizes innovation and technology development, focusing on chemical and biological technology platforms to meet evolving R&D demands[54]. - The company has established a sound governance structure, with independent committees providing professional decision-making support to the board[108]. - The company has implemented a financial decision-making process in accordance with its articles of association, allowing for independent financial management[112]. - The company has not reported any significant changes in accounting policies or principles related to hedging activities compared to the previous reporting period[82]. Environmental Responsibility - The company has complied with various environmental protection laws and standards applicable to its operations[192]. - The company has received multiple environmental impact assessment approvals for its new drug research and development projects from 2010 to 2021[192]. - The company has a wastewater treatment project in Xi'an with a capacity of 120 tons/day, which received environmental impact report approval in August 2020[195]. - The company reported a total wastewater discharge of 10.088 tons for CODcr, with no exceedance of discharge standards[199]. Workforce and Talent Management - The company expanded its workforce to 19,481 employees by the end of 2022, with 89.35% in R&D, production technology, and clinical services[30]. - The number of R&D personnel grew by 29.36% to 17,406, with a slight decrease in the proportion of R&D personnel to total staff[66]. - The company has implemented a talent development platform, including internal training and partnerships with renowned institutions, to attract and cultivate top global talent[55]. - The company has established a comprehensive training program to enhance employee skills and align personal development with corporate strategy[160]. Financial Management - The company has established a robust internal control and audit system to monitor financial activities and identify risks[185]. - The company has enhanced its financial reporting and tax management systems, improving efficiency and accuracy in financial forecasting and tax risk assessment[181]. - The company has integrated its subsidiaries into a unified management system, ensuring accurate consolidated financial reporting and operational efficiency[184]. - The total pre-tax remuneration for the company's directors, supervisors, and senior management in 2022 amounted to CNY 1,339.22 million[148].

证券代码：300759 证券简称：康龙化成 公告编号：2023-022 康龙化成（北京）新药技术股份有限公司 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）定于 2023 年 4 月 21 日（星期五）15:00-17:00 在全景网举办 2022 年度业绩说明会，本次年度 业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动 平台"（http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长兼总经理 Boliang Lou 先生、财务负 责人兼董事会秘书李承宗先生、独立非执行董事李丽华女士、东方证券承销保荐 有限公司保荐代表人郑睿先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 20 日（星期四）15:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进入 问 ...